Lymphoid leukemia
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]
For patient information, click here
| Lymphoid leukemia | |
| ICD-10 | C91 |
|---|---|
| ICD-9 | 204 |
| MeSH | D007945 |
|
Lymphoid leukemia Main Page |
Overview
Classification
The World Health Organization (WHO) classifications and French-American-British (FAB) for acute lymphoblastic leukemia (ALL) are provided below.[1] [2][3][4]
- WHO classification of acute lymphoblastic leukemia
- B lymphoblastic leukemia/lymphoma:
- B lymphoblastic leukemia/lymphoma, NOS
- B lymphoblastic leukemia/lymphoma:
- B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities:
- B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2), BCR-ABL1[5]
- B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged[6]
- B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22) TEL-AML1 (ETV6-RUNX1)[7]
- B lymphoblastic leukemia/lymphoma with hyperdiploidy
- B lymphoblastic leukemia/lymphoma with hypodiploidy[8]
- B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32) IL3-IGH
- B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3) TCF3-PBX1
- B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities:
- T lymphoblastic leukemia/lymphoma:
- FAB classification of acute lymphoblastic leukemia (for historical purposes):[9]
- ALL-L1: Small cells with homogeneous nuclear chromatin, a regular nuclear shape, small or no nucleoli, scanty cytoplasm, and mild to moderate basophilia
- ALL-L2: Large, heterogeneous cells with variable nuclear chromatin, an irregular nuclear shape, 1 or more nucleoli, a variable amount of cytoplasm, and variable basophilia
- ALL-L3: Large, homogeneous cells with fine, stippled chromatin; regular nuclei; prominent nucleoli; and abundant, deeply basophilic cytoplasm. The most distinguishing feature is prominent cytoplasmic vacuolation.
- FAB classification of acute lymphoblastic leukemia (for historical purposes):[9]
- T lymphoblastic leukemia/lymphoma:
Pathophysiology
References
- ↑ Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (May 2016). "The 2016 revision of the World Health Organization classification of lymphoid neoplasms". Blood. 127 (20): 2375–90. doi:10.1182/blood-2016-01-643569. PMC 4874220. PMID 26980727.
- ↑ Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (December 1999). "The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997". Ann. Oncol. 10 (12): 1419–32. PMID 10643532.
- ↑ Makar AB, McMartin KE, Palese M, Tephly TR, Schmoldt A, Benthe HF, Haberland G, Anke H, Spector LB (June 1975). "Formate assay in body fluids: application in methanol poisoning". Biochem Med. 13 (2): 117–26. PMC 5922622. PMID 1.
- ↑ Wang Y, Miller S, Roulston D, Bixby D, Shao L (July 2016). "Genome-Wide Single-Nucleotide Polymorphism Array Analysis Improves Prognostication of Acute Lymphoblastic Leukemia/Lymphoma". J Mol Diagn. 18 (4): 595–603. doi:10.1016/j.jmoldx.2016.03.004. PMID 27161658.
- ↑ Goud TM, Al Salmani KK, Al Harasi SM, Al Musalhi M, Wasifuddin SM, Rajab A (2015). "Importance of FISH combined with Morphology, Immunophenotype and Cytogenetic Analysis of Childhood/ Adult Acute Lymphoblastic Leukemia in Omani Patients". Asian Pac. J. Cancer Prev. 16 (16): 7343–50. PMID 26514535.
- ↑ Nagayama J, Tomizawa D, Koh K, Nagatoshi Y, Hotta N, Kishimoto T, Takahashi Y, Kuno T, Sugita K, Sato T, Kato K, Ogawa A, Nakahata T, Mizutani S, Horibe K, Ishii E (June 2006). "Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group". Blood. 107 (12): 4663–5. doi:10.1182/blood-2005-11-4728. PMID 16478880.
- ↑ Peter A, Heiden T, Taube T, Körner G, Seeger K (November 2009). "Interphase FISH on TEL/AML1 positive acute lymphoblastic leukemia relapses--analysis of clinical relevance of additional TEL and AML1 copy number changes". Eur. J. Haematol. 83 (5): 420–32. doi:10.1111/j.1600-0609.2009.01315.x. PMID 19594616.
- ↑ Greipp PR, Trendle MC, Leong T, Oken MM, Kay NE, Van Ness B, Kyle RA (September 1999). "Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?". Leuk. Lymphoma. 35 (1–2): 83–9. doi:10.3109/10428199909145707. PMID 10512165.
- ↑ Canaani J, Beohou E, Labopin M, Socié G, Huynh A, Volin L, Cornelissen J, Milpied N, Gedde-Dahl T, Deconinck E, Fegueux N, Blaise D, Mohty M, Nagler A (April 2017). "Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT". Am. J. Hematol. 92 (4): 344–350. doi:10.1002/ajh.24640. PMID 28052366.